Status:
COMPLETED
Initiation of Ovarian Stimulation With Recombinant-human FSH (Bemfola®) in the Late Follicular Phase
Lead Sponsor:
Universitair Ziekenhuis Brussel
Conditions:
Infertility, Female
Eligibility:
FEMALE
18-36 years
Phase:
PHASE3
Brief Summary
A randomised controlled open-label clinical trial to compare the outcome parameters after ovarian stimulation using recombinant-human FSH (follicle stimulating hormone), starting on day 2 of the cycle...
Detailed Description
Objective: To determine whether late follicular stimulation using recombinant-human FSH has comparable outcomes to treatment using recombinant-human FSH in early follicular phase in a flexible GnRH (G...
Eligibility Criteria
Inclusion
- oocyte donor patients
- Age from 18 to 36 years
- BMI 19 to 35
- Regular menstrual cycle length i.e. 24-35 days
Exclusion
- Patients with AMH \<1.1 ng/ml and/or AFC\<7
- Patients with FNPO (Follicle Number Per Ovary) ≥ 19 and/ord AMH \>5ng/ml
- Endometriosis grade 3-4
- Oligo-amenorrhea
- Any untreated endocrine abnormality
Key Trial Info
Start Date :
November 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 25 2022
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT03767218
Start Date
November 1 2018
End Date
November 25 2022
Last Update
May 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitair Ziekenhuis Brussel
Brussels, Belgium, 1090